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Lung tumours are the leading cause of cancer deaths, accounting
for 150 000 deaths/year in the USA (Parker et al, 1996) and 30 000
deaths/year in Italy (Zanetti et al, 1998). Approximately 80% of
these tumours are non-small cell lung cancers (NSCLC), most of
which are diagnosed in an advanced phase and are thus not suit-
able for local–regional treatment; overall survival at 5 years is
only 10–15% (Bunn, 1993).
In the case of tumours that have spread beyond surgically treat-
able limits (locally advanced and/or metastastatic disease),
cisplatin-containing chemotherapeutic regimens have recently
been found to be effective not only in terms of response, but also in
terms of an, albeit limited, increase in overall survival (Souquet et
al, 1993; NSCLCCG, 1995). However, a large number of subjects
are not even considered for this treatment because the toxic nature
of cisplatin means that it is contraindicated in patients with heart
or kidney diseases, as well as in those whose general physical
condition is poor.
As a result, new drugs with demonstrated activity against
NSCLC, such as the taxanes (Gatzemeier et al, 1995; Fossella et
al, 1995), topoisomerase inhibitors (Fukuoka et al, 1992), gem-
citabine (Noble and Goa, 1997) and vinorelbine (Lilenbaum and
Grece, 1993; Goss et al, 1997) have aroused considerable interest.
In particular, vinorelbine has been shown to increase survival in
patients aged more than 70 years in comparison with the best
supportive care alone (ELCVISG, 1999), and the favourable toxi-
cological profile of gemcitabine allows its use in both unfit and
elderly patients.
When administered alone, both gemcitabine and vinorelbine
have been found to be effective in approximately 20% of the
studied patients (including cisplatin-resistant cases). There are few
data concerning their combined use, although the most tolerated
schedule seems to be the administration of gemcitabine 1000 mg
m–2 and vinorelbine 25 mg m–2 on day 1 and 8 every 21 days.
The activity of the drugs and the tolerability of this combination
prompted us to test it in patients with NSCLC. We first used it in
patients who had previously tolerated a cisplatin-containing
regimen well and observed a response rate of approximately 13%
(with 50% of the patients reaching stable disease). This encour-
aging result led us to extend its use to chemotherapy-naive patients
aged more than 65 years and those whose compromised perfor-
mance status or concomitant diseases contraindicated the adminis-
tration of cisplatin.
The primary objectives of this non-randomized phase II study
were to determine the efficacy and toxicity of the combination in
elderly or unfit chemotherapy-naive NSCLC patients.
MATERIALS AND METHODS
Patients
Since March 1997, we have used the gemcitabine plus vinorelbine
combination to treat 43 previously untreated stage III (24) or stage
IV (19) NSCLC patients (36 males and seven females, with 
a median age of 66 years: range 48–75), who were considered
ineligible for cisplatin treatment on the ground of their age or the
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aged less than 65 years, 13 had an ECOG performance status of
≥ 2, and four concomitant kidney or heart disease (Table 2).
The four stage IIIa patients included in the study were more
than 65 years old, presented contraindications against surgery, and
their respiratory function made them ineligible for radiotherapy.
Treatment regimen
The chemotherapeutic regimen consisted of one intravenous dose
of gemcitabine 1000 mg m–2 in 100 ml of normal saline adminis-
tered over 30 min, followed by an i.v. vinorelbine bolus of 
25 mg m–2 administered over 2 min. 250 ml of normal saline were
subsequently administered over 15 min in order to wash out the
vein. The treatment was given on days 1 and 8, and repeated every
3 weeks.
The anti-emetic treatment was ondansetron 8 mg in 100 cc of
normal saline administered 15 min before the chemotherapy, with
a further 4 mg being given per os in the evening of the same day.
The patients subsequently received metoclopramide 10 mg i.m. as
needed.
Blood counts were performed on days 7, 14 and 20. Liver and
kidney function was checked on day 20. In the case of an incom-
plete recovery of haematological values by day 20, the therapy
was delayed for 1 week. The planned dose was reduced by 25%
only in the case an incomplete haematological recovery on day 27
or grade 4 toxicity.
Statistical considerations
In accordance with the optimal two-stage phase II design, the treat-
ment programme was designed to reject a response rate of less than
20% (p0) and provide a statistical power of 80% in assessing the
activity of the regimen (in terms of response rate) as 40% (p1) 
(p1 – p0 = 20%) with an alpha error of less than 0.05 (Simon, 1989).
Forty-three patients were therefore required: 13 for the first and
30 for the second step.
RESULTS
Of the 43 patients originally included in the trial, three failed to
complete the first treatment cycle (one died early, one developed
pulmonary cavitation with superinfection, and one refused to
continue therapy in our Centre) but were nevertheless included in
the response and toxicity evaluations. The median follow-up was
11 months (range: 4–21).
All of the evaluable patients completed at least two treatment
cycles, with a median of four cycles per patient (range 0.5–6) for a
total of 146 cycles; their measurable lesions were evaluated instru-
mentally.
Fifteen patients (34.9%) achieved partial remission (95% confi-
dence interval: 27.6–42.2%), with a median response duration of 6
months; the median survival of these patients has not yet been
reached. A further 15 had stable disease for a median of 4 months
and a median survival of 7 months. The ten patients (23.2%) who
experienced disease progression had a median survival of 4
months.
The survival curves (Figure 1 and 2) show an advantage for
stage III over stage IV patients, and for responders in comparison
with those who progressed; the survival of the patients with stable
disease overlapped that of the patients as a whole.
Ten of the patients with stage IIIb disease received radiotherapy
after completing the chemotherapy programme; the two who
responded well to both chemo- and radiotherapy also underwent
complete surgical resection, the histological results of which
revealed the presence of active adenocarcinomas.
The treatment was well tolerated: only 35% of the patients
experienced episodes of grade 3 or 4 granulocytopenia, all of
which occurred occurred on day 14 without any symptoms or
fever. There was no need for antibiotics and hospital admission.
There was no evidence of any severe haematological toxicity at
the time of recycling. Grade 3 thrombocytopenia was observed in
9% of the patients but, once again, only at the nadir.
Gastrointestinal tolerance was excellent, with only 9% of the
patients developing short-lived grade 3 toxicity (nausea and
vomiting). Increased transaminase levels (less than double normal
values) were observed in 11.6% of the patients, but were always
reversible.
The excellent tolerability of this combination enabled us to
administer an average of 93% of the planned dose (99.2%
excluding the inevaluable patients) at a mean dose intensity 
of 92%.
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Table 1 Patient characteristics
No. of patients 43
Age (years)
median 66
range 48–75
Sex (M/F) 36/7
Performance status (ECOG)
01 1
11 9
21 3
Stage
III A 4
III B 20
IV 19
Histological type
Adenocarcinoma 17
Epidermoid 11
NSCLC NAS 12
Large cells 1
Bronchiolo-alveolar 1
Mixed 1
Metastatic sites
Brain 3
Liver 6
Adrenal gland 4
Bone 6
Lung 6
Table 2 Physical condition of the patients
Age Performance status Comorbidity
Patients (ECOG)
(n)012
> 65 26 11 15 0 –
< 65 13 0 0 13 –
< 65 4 0 4 0 2 with nephropathy
2 with cardiopathyDISCUSSION
The ASCO guidelines for the treatment of NSCLC recommend the
use of cisplatin-containing combinations because these have been
shown to improve survival in comparison with the best supportive
treatments (NSCLCEP, 1997). However, the toxic effects of these
combinations (particularly on the kidneys, which require greater
hydration) contraindicate their use in both nephropathic and
cardiopathic patients. Severe and prolonged cisplatin-induced
nausea and/or vomiting is another major limitation that can only be
partially controlled by modern anti-emetics.
Some studies have shown that carboplatin has the same activity
and is better tolerated (Klastersky et al, 1990), but at the cost of
greater haematological toxicity. Other more recent studies have
shown that taxanes are also active against NSCLC (especially
when associated with platinum derivatives) and may lead to even
50% objective response rates (Langer et al, 1995; Bonomi, 1999).
However, as in the case of those based on cisplatin, the toxicity of
these combinations limits their use to patients with good or excel-
lent general health.
A phase I study of the combination of cisplatin, gemcitabine and
vinorelbine found an objective response rate in 51% of NSCLC
patients, but 26% experienced grade 4 neutropenia (Frasci et al, 1997).
Our study was specifically designed to evaluate the feasibility
and activity of gemcitabine plus vinorelbine in patients whose age,
concomitant diseases or general physical condition normally
excludes the use of aggressive treatment programmes. The
response rate was better than that reported when the two drugs are
administered separately, and similar to that obtained using the
first-generation cisplatin combination. It is also worth noting that
the 1-year actuarial survival rate is 31.1% and that the median
survival of the responsive patients has not been reached after 20
months. However, it must be pointed out that ten of the responding
patients also received radiotherapy and so not all of the survival
benefit can be attributed to the chemotherapy.
The fact that 10% of the patients in stage IIIb were able to
undergo surgery despite their age or poor condition suggests that
the combination could also be tested as a neo-adjuvant treatment.
The tolerability of the treatment is further underlined by the fact
that there was almost complete concordance between the planned
treatment schedule and the actually administered doses.
The doses were selected on the basis of their feasibility and
optimal tolerability. In particular, the decision not to administer the
treatment on day 15 made it possible to reduce haematological
toxicity to a significant extent. Although only two full papers
(Isokangeas et al, 1999; Lortusso et al, 2000) have so far been
published concerning this treatment regimen, a number of
abstracts have been submitted to international congresses
describing the use of these two drugs in phase I or II trials (see
Table 3). In these studies, the results obtained using various doses
were no better than ours, whereas a similar treatment regimen
administered up to day 15 led to a toxic death rate of 5%(Feliu et
al, 1998).
In conclusion, despite the fact that the 1-year survival is similar to
that achieved with vinorelbine alone (LeChevallier, 1996) and that
there is therefore still a need to compare the results obtained using the
combination with those obtained using the single agent, it can be said
that the administration of gemcitabine plus vinorelbine is effective
and well tolerated by NSCLC patients, and that its excellent safety
profile encourages its use in elderly and unfit patients.
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Table 3 Phase II studies of gemcitabine (GEM) plus vinorelbine (NVB)
Author Phase NVB – GEM Timing Patients OR*
(mg) (day) (n) (%)
Esteban 1998 I–II 30–1250 1,8 32 43.3
Cigolari 1998 I–II 25–1000 1,8 25 36
25–1200 25 20
Lilenbaum 1998 II 25–1250 1,8 13 27
Feliu 1998 II 25–1000 1,8,15 36 22.5
De Candis 1998 II 25–1250 1,8 32 34
Isokangas 1999 I–II 30–1000 1,8,15
45 40
35–1200 1,15
Lorusso 2000 I–II 30–1200 1,8 52 36
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